BULLISHWHALES
BullishWhales · Analysts · Analyst Profile
BW Score Rank#28 of 347

Jonathan Wolleben

JMP Securities · Equity Research Analyst
EstablishedRating since 2022No new ratings since May 2025

Analyst rating accuracy & track record

Jonathan Wolleben is an equity research analyst at JMP Securities. Bullish Whales has scored 51 of their stock calls across 19 companies. Their picks beat their sector 45% of the time over the next 12 months, and their price targets were reached 36% of the time within a year.

Win % vs sector
45%
PT Hit % (12mo)
36%
Avg sector-excess
+5.1%
Scored calls
51
Tickers
19
Tier
Established

Track record

Bullish Whales has scored 51 of Jonathan Wolleben's stock calls across 19 companies, dating back to 2022. Their rated stocks beat their own sector 45% of the time over the next 12 months. On a typical call, a Wolleben pick returned +5.1% more than its sector over the following year.

Of the scored calls, 51 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
DBVTDBV Technologies
Buy$21.00May 2025+82.7%Hit
AURAAura Biosciences Inc
Buy$19.00May 2025+12.7%Miss
MBXMBX Biosciences, Inc. Common Stock
Buy$38.00Apr 2025+308.8%Hit
ALTAltimmune Inc
Buy$25.00Apr 2025−29.5%Miss
KALVKalvista Pharmaceuticals Inc
Buy$19.00Mar 2025+51.2%Hit
SKYESkye Bioscience, Inc. Common Stock
Buy$15.00Mar 2025−72.8%Miss
ALTAltimmune Inc
Buy$25.00Mar 2025−44.1%Miss
DBVTDBV Technologies
Buy$10.00Mar 2025+406.5%Hit
OCULOcular Therapeutix Inc
Buy$19.00Mar 2025+47.6%Miss
KALVKalvista Pharmaceuticals Inc
Buy$19.00Mar 2025+30.9%Hit
BCRXBioCryst Pharmaceuticals Inc
Buy$18.00Mar 2025−3.1%Miss
PHVSPharvaris BV
Buy$55.00Mar 2025+65.7%Miss
GPCRStructure Therapeutics Inc. American Depositary Shares
Buy$87.00Feb 2025+173.7%Hit
BCRXBioCryst Pharmaceuticals Inc
Buy$18.00Feb 2025−18.3%Miss
KALVKalvista Pharmaceuticals Inc
Buy$19.00Jan 2025+67.3%Hit
PHVSPharvaris BV
Buy$55.00Jan 2025+52.6%Miss
DBVTDBV Technologies
Buy$10.00Jan 2025+218.2%Hit
SVRASavara Inc
Buy$9.00Dec 2024+73.0%Miss
HGVHilton Grand Vacations Inc
Buy$50.00Dec 2024+7.4%Hit
PRQRProQR Therapeutics BV
Buy$8.00Dec 2024−28.9%Miss
DBVTDBV Technologies
Buy$10.00Dec 2024+499.0%Hit
SVRASavara Inc
Buy$9.00Oct 2024−4.7%Miss
SKYESkye Bioscience, Inc. Common Stock
Buy$15.00Sep 2024−24.9%Miss
SVRASavara Inc
Buy$9.00Sep 2024−3.7%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$32.00Aug 2024+188.3%Miss
SVRASavara Inc
Buy$9.00Aug 2024−25.9%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$48.00Jun 2024+16.5%Miss
LRMRLarimar Therapeutics Inc
Buy$25.00May 2024−69.1%Miss
SGMTSagimet Biosciences Inc. Series A Common Stock
Buy$48.00May 2024−29.1%Miss
LRMRLarimar Therapeutics Inc
Buy$25.00May 2024−66.8%Miss
ALTAltimmune Inc
Buy$24.00May 2024−14.8%Miss
RLYBRallybio Corp
Buy$8.00Apr 2024−81.6%Miss
RLYBRallybio Corp
Buy$8.00Apr 2024−81.9%Miss
PHVSPharvaris BV
Buy$50.00Apr 2024−45.3%Miss
SPRBSpruce Biosciences, Inc. Common Stock
Buy$3.00Mar 2024−59.8%Miss
RLYBRallybio Corp
Buy$8.00Mar 2024−59.0%Miss
CRNXCrinetics Pharmaceuticals Inc
Buy$60.00Mar 2024−8.4%Hit
PHVSPharvaris BV
Buy$49.00Feb 2024−37.4%Miss
RLYBRallybio Corp
Buy$8.00Feb 2024−54.4%Miss
PHVSPharvaris BV
Buy$49.00Jan 2024−36.9%Miss
RLYBRallybio Corp
Buy$16.00Sep 2023−100.6%Miss
DBVTDBV Technologies
Buy$4.00Aug 2023−81.1%Miss
PRQRProQR Therapeutics BV
Buy$6.00May 2023−3.2%Miss
ALTAltimmune Inc
Buy$15.00May 2023+31.4%Miss
PHVSPharvaris BV
Buy$20.00May 2023+156.7%Hit
PHVSPharvaris BV
Buy$20.00Apr 2023+162.1%Hit
PRQRProQR Therapeutics BV
Buy$6.00Mar 2023−12.2%Miss
PHVSPharvaris BV
Buy$23.00Feb 2023+184.7%Hit
PHVSPharvaris BV
Buy$23.00Jan 2023+204.8%Hit
PHVSPharvaris BV
Buy$22.00Dec 2022+189.1%Hit
Go to

Jonathan Wolleben: analyst track record FAQ

Is Jonathan Wolleben a good stock analyst?

Yes, by track record. Jonathan Wolleben ranks number 28 of 347 of the analysts Bullish Whales scores, with a BW Score of 65 out of 100. Past results do not guarantee future ones.

What is Jonathan Wolleben's win rate?

Jonathan Wolleben's win rate is 45%. Across 51 scored calls, their rated stocks beat their sector 45% of the time over the next 12 months. On a typical call they returned +5.1% more than the sector.

What stocks and sectors does Jonathan Wolleben cover?

Jonathan Wolleben covers 19 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Jonathan Wolleben's price targets accurate?

Jonathan Wolleben's price targets are reached within 12 months 36% of the time. The base rate across all analysts Bullish Whales tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Bullish Whales scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Jonathan Wolleben's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Bullish Whales score analyst accuracy?

Bullish Whales scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Jonathan Wolleben rank among Wall Street analysts?

Jonathan Wolleben ranks number 28 of 347 by BW Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30